Aspire Biopharma Files 8-K: Director Changes & Officer Appointments
Ticker: ASBPW · Form: 8-K · Filed: Jun 10, 2025 · CIK: 1847345
Sentiment: neutral
Topics: leadership-change, corporate-governance, filing
Related Tickers: ASBP
TL;DR
Aspire Biopharma shakes up board and exec team, files 8-K.
AI Summary
Aspire Biopharma Holdings, Inc. filed an 8-K on June 10, 2025, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory arrangements. The filing also includes a Regulation FD Disclosure and financial statements/exhibits. The company was formerly known as PowerUp Acquisition Corp. and PowsedrUp Acquisition Corp.
Why It Matters
This filing indicates significant changes in the company's leadership and governance structure, which could impact its strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially if related to performance or strategy, can introduce uncertainty and potential shifts in company direction.
Key Players & Entities
- Aspire Biopharma Holdings, Inc. (company) — Registrant
- PowerUp Acquisition Corp. (company) — Former company name
- PowsedrUp Acquisition Corp. (company) — Former company name
- June 10, 2025 (date) — Date of report
FAQ
What specific reasons were given for the departure of any directors or officers?
The filing indicates the departure of directors or certain officers as an item of information but does not provide specific reasons within the provided text.
Who are the newly elected directors or appointed officers?
The filing lists 'Election of Directors' and 'Appointment of Certain Officers' as items of information, but the names of the individuals are not detailed in the provided text.
What are the details of the compensatory arrangements for the officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item, but the specifics of these arrangements are not included in the provided text.
What is the significance of the Regulation FD Disclosure?
The Regulation FD Disclosure indicates that the company is making public disclosures to prevent selective disclosure of material non-public information.
What financial statements or exhibits are included with this filing?
The filing states 'Financial Statements and Exhibits' are included, but the specific content of these exhibits is not detailed in the provided text.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 10, 2025 regarding Aspire Biopharma Holdings, Inc. (ASBPW).